69 related articles for article (PubMed ID: 23416067)
1. BH3 mimetics reduce adhesion and migration of hepatoblastoma and hepatocellular carcinoma cells.
Vogt F; Lieber J; Dewerth A; Hoh A; Fuchs J; Armeanu-Ebinger S
Exp Cell Res; 2013 Jun; 319(10):1443-50. PubMed ID: 23416067
[TBL] [Abstract][Full Text] [Related]
2. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma.
Lieber J; Ellerkamp V; Vogt F; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Exp Cell Res; 2014 Mar; 322(1):217-25. PubMed ID: 24355809
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
4. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.
Lieber J; Armeanu-Ebinger S; Fuchs J
Int J Mol Sci; 2015 Feb; 16(2):4190-208. PubMed ID: 25690034
[TBL] [Abstract][Full Text] [Related]
5. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
6. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma.
Lieber J; Eicher C; Wenz J; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
BMC Cancer; 2011 Aug; 11():362. PubMed ID: 21854558
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells.
Lieber J; Ellerkamp V; Wenz J; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2012 Feb; 28(2):149-59. PubMed ID: 21971946
[TBL] [Abstract][Full Text] [Related]
8. Comparison of in vitro antileukemic activity of obatoclax and ABT-737.
Opydo-Chanek M; Mazur L
Tumour Biol; 2016 Aug; 37(8):10839-49. PubMed ID: 26880588
[TBL] [Abstract][Full Text] [Related]
9. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
10. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
[TBL] [Abstract][Full Text] [Related]
11. Cell Death Induction by the Indirubin Derivative 7BIO and the BH3 Mimetic Drugs ABT-737 and GX15-070 in Medullary Thyroid Carcinoma Cells.
Broecker-Preuss M; Becher-Boveleth N; Mann K
Exp Clin Endocrinol Diabetes; 2016 May; 124(5):324-30. PubMed ID: 26849668
[TBL] [Abstract][Full Text] [Related]
12. BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.
Galmiche A; Ezzoukhry Z; François C; Louandre C; Sabbagh C; Nguyen-Khac E; Descamps V; Trouillet N; Godin C; Regimbeau JM; Joly JP; Barbare JC; Duverlie G; Mazière JC; Chatelain D
Mol Cancer Res; 2010 Aug; 8(8):1116-25. PubMed ID: 20647330
[TBL] [Abstract][Full Text] [Related]
13. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
[TBL] [Abstract][Full Text] [Related]
14. Activation of caspases-9, -3 and -8 in human platelets triggered by BH3-only mimetic ABT-737 and calcium ionophore A23187: caspase-8 is activated via bypass of the death receptors.
Mutlu A; Gyulkhandanyan AV; Freedman J; Leytin V
Br J Haematol; 2012 Dec; 159(5):565-71. PubMed ID: 23025479
[TBL] [Abstract][Full Text] [Related]
15. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
[TBL] [Abstract][Full Text] [Related]
16. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
17. BH3 mimetics suppress CXCL12 expression in human malignant peripheral nerve sheath tumor cells.
Graham CD; Kaza N; Pruitt HC; Gibson LM; Klocke BJ; Shevde LA; Carroll SL; Roth KA
Oncotarget; 2017 Jan; 8(5):8670-8678. PubMed ID: 28055968
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
19. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW
Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525
[TBL] [Abstract][Full Text] [Related]
20. The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid.
Romani AA; Desenzani S; Morganti MM; Baroni MC; Borghetti AF; Soliani P
Cancer Chemother Pharmacol; 2011 Mar; 67(3):557-67. PubMed ID: 20473610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
